相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram
Liangyou Gu et al.
SCIENTIFIC REPORTS (2016)
Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients
Xiaobin Gu et al.
SCIENTIFIC REPORTS (2016)
Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer
D. J. Pinato et al.
BRITISH JOURNAL OF CANCER (2014)
Epidemiologic and Molecular Prognostic Review of Glioblastoma
Jigisha P. Thakkar et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme
R. M. Bambury et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience
L. R. Molife et al.
ANNALS OF ONCOLOGY (2012)
Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
Ignacio Garrido-Laguna et al.
CANCER (2012)
Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma
Lola B. Chambless et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need
Mrinal M. Gounder et al.
CLINICAL CANCER RESEARCH (2011)
Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma
Andrzej Hellmann et al.
CLINICAL PHARMACOKINETICS (2011)
It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Revisiting the role of molecular targeted therapies in patients with brain metastases
Dionysis Papadatos-Pastos et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Association Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma
Rachel L. Derr et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas
Matthew J. McGirt et al.
NEUROSURGERY (2008)
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials
TG Roberts et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
MD Prados et al.
NEURO-ONCOLOGY (2004)
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors - Report of the Quality Standards Subcommittee of the American Academy of Neurology
MJ Glantz et al.
NEUROLOGY (2000)
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials
T Bachelot et al.
ANNALS OF ONCOLOGY (2000)
分享论文
